SCN9A and cancer: On the other hand, for cancer types that exhibit uniquely higher expression of NaV1.7 compared to other subtypes, such as GC and EC, utilizing selective NaV1.7 inhibitors targeting VSDII and VSDIV binding sites (Payandeh and Hackos, 2018; Mulcahy et al., 2019) would be more appropriate.